CN105232540A - Drug combination for treating infection after burn - Google Patents
Drug combination for treating infection after burn Download PDFInfo
- Publication number
- CN105232540A CN105232540A CN201510629893.0A CN201510629893A CN105232540A CN 105232540 A CN105232540 A CN 105232540A CN 201510629893 A CN201510629893 A CN 201510629893A CN 105232540 A CN105232540 A CN 105232540A
- Authority
- CN
- China
- Prior art keywords
- compound
- burn
- infections
- pharmaceutical composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 23
- 239000000890 drug combination Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 241000588624 Acinetobacter calcoaceticus Species 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000004531 microgranule Substances 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 229920001817 Agar Polymers 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- -1 antiseptic Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a drug combination for treating infection after burn. The drug combination comprises a compound in effective quantity and a pharmaceutically-acceptable carrier, and structure of the compound is shown as follows. The compound has remarkable effect on pathogenic bacteria causing infection after burn, and can be developed into a novel drug combination which is clinically effective.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of infections after burn.
Background technology
Infections after burn is common clinical frequently-occurring disease, and the cause of disease is many caused by cause pathogeny imcrobe infection, causes the pathogenic microorganism of infection to mainly contain antibacterial, virus and mycoplasma, chlamydia.Find after deliberation, in the secretions at patient infection position, various pathogens detected, find that in the recent period Venice acinetobacter calcoaceticus ATCC31012 is also one of pathogenic bacterium wherein.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of infections after burn.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of infections after burn, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of infections after burn, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizing agent or corrigent.
Preferably, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
Preferably, described diluent is lactose.
Preferably, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment infections after burn, and this compound has having structure:
Preferably, described infections after burn is caused by Venice acinetobacter calcoaceticus ATCC31012.
The present invention also provides the purposes of compound in the medicine of preparation vitro inhibition Venice acinetobacter calcoaceticus ATCC31012, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or diluent.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its compositions.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, disperse medium, coating material, surfactant, antioxidant, antiseptic (such as antibacterial, antifungal), isotonic agent, absorption delay agent, salt, antiseptic, drug stabilizing agent, binding agent, excipient, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of active component, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for the pathogen Be very effective causing infections after burn, can be developed to pharmaceutical composition effectively new clinically.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The research of the purposes of experimental example the compounds of this invention in the medicine of preparation vitro inhibition Venice acinetobacter calcoaceticus ATCC31012
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of compound is:
For examination strain Venice acinetobacter calcoaceticus ATCC31012 purchased from Fu Xiang bio tech ltd, Shanghai.
Culture fluid
Nutrient agar and nutrient broth, purchased from Chen Yu experimental facilities company limited of BeiJing ZhongKe.
Test method
Venice acinetobacter calcoaceticus ATCC31012 is inoculated in agar plate nutritional solution plane, evenly gathers during inoculation.
Take target compound 0.12 gram, add 5000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritional solution plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of bacterial restrain.Measure and average for 3 times.
1.4 result
The average diameter of the bacterial restrain of Venice acinetobacter calcoaceticus ATCC31012 is 13.86mm, and this shows that target compound has the effect of extremely strong suppression Venice acinetobacter calcoaceticus ATCC31012.
Claims (9)
1. treat a compound for infections after burn, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for infections after burn, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of infections after burn according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizing agent or corrigent.
4. the pharmaceutical composition for the treatment of infections after burn according to claim 3, is characterized in that, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
5. the pharmaceutical composition for the treatment of infections after burn according to claim 4, is characterized in that, described diluent is lactose.
6. the pharmaceutical composition for the treatment of infections after burn according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment infections after burn, it is characterized in that, this compound has having structure:
8. purposes according to claim 7, is characterized in that, described infections after burn is caused by Venice acinetobacter calcoaceticus ATCC31012.
9. the purposes of compound in the medicine of preparation vitro inhibition Venice acinetobacter calcoaceticus ATCC31012, it is characterized in that, this compound has having structure:
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510629893.0A CN105232540A (en) | 2015-09-29 | 2015-09-29 | Drug combination for treating infection after burn |
| CN201710122496.3A CN106806367A (en) | 2015-09-29 | 2015-09-29 | A kind of pharmaceutical composition for treating infections after burn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510629893.0A CN105232540A (en) | 2015-09-29 | 2015-09-29 | Drug combination for treating infection after burn |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710122496.3A Division CN106806367A (en) | 2015-09-29 | 2015-09-29 | A kind of pharmaceutical composition for treating infections after burn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105232540A true CN105232540A (en) | 2016-01-13 |
Family
ID=55030540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710122496.3A Withdrawn CN106806367A (en) | 2015-09-29 | 2015-09-29 | A kind of pharmaceutical composition for treating infections after burn |
| CN201510629893.0A Pending CN105232540A (en) | 2015-09-29 | 2015-09-29 | Drug combination for treating infection after burn |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710122496.3A Withdrawn CN106806367A (en) | 2015-09-29 | 2015-09-29 | A kind of pharmaceutical composition for treating infections after burn |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN106806367A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105777612A (en) * | 2016-03-07 | 2016-07-20 | 王保亮 | Medicine composition for treating children recurrent respiratory infection |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070238782A1 (en) * | 2006-04-07 | 2007-10-11 | Sunten Phytotech Co., Ltd. | Naphthalenedione Compounds |
| CN101553471A (en) * | 2006-12-06 | 2009-10-07 | 詹森药业有限公司 | Antibacterial quinoline derivatives |
-
2015
- 2015-09-29 CN CN201710122496.3A patent/CN106806367A/en not_active Withdrawn
- 2015-09-29 CN CN201510629893.0A patent/CN105232540A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070238782A1 (en) * | 2006-04-07 | 2007-10-11 | Sunten Phytotech Co., Ltd. | Naphthalenedione Compounds |
| CN101553471A (en) * | 2006-12-06 | 2009-10-07 | 詹森药业有限公司 | Antibacterial quinoline derivatives |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105777612A (en) * | 2016-03-07 | 2016-07-20 | 王保亮 | Medicine composition for treating children recurrent respiratory infection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106806367A (en) | 2017-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105198903A (en) | Pharmaceutical composition for treating acute upper respiratory infection | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105748478B (en) | A kind of medicine treating infantile diarrhea | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection | |
| CN105254700A (en) | Medicinal composition for treatment of infection after scald | |
| CN105687189A (en) | Medicine composition for treating upper respiratory tract infection | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105111185A (en) | Pharmaceutical composition for treating vaginitis of elder people | |
| CN105560234A (en) | Medicine composition for treating oral and maxillofacial inflammation | |
| CN105348270A (en) | Medicine composition preventing dental body and dental pulp infection | |
| CN105254477A (en) | Medicine composition for treatment of vaginitis | |
| CN105777612A (en) | Medicine composition for treating children recurrent respiratory infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160113 |